MyImatinib - Oncology Therapy
Targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with the tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors.
-
Most popular related searches
Customer reviews
No reviews were found for MyImatinib - Oncology Therapy. Be the first to review!